Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

被引:9
|
作者
Rade, Michael [1 ]
Grieb, Nora [2 ,3 ]
Weiss, Ronald [1 ,4 ]
Sia, Jaren [5 ]
Fischer, Luise [2 ]
Born, Patrick [2 ]
Boldt, Andreas [4 ]
Fricke, Stephan [4 ]
Franz, Paul [4 ]
Scolnick, Jonathan [5 ]
Venkatraman, Lakshmi [5 ]
Xu, Stacy [5 ]
Kloetzer, Christina [2 ]
Heyn, Simone [2 ]
Kubasch, Anne Sophie [2 ]
Baber, Ronny [6 ,7 ]
Wang, Song Yau [2 ]
Bach, Enrica [2 ]
Hoffmann, Sandra [2 ]
Ussmann, Jule [2 ]
Schetschorke, Birthe [2 ]
Hell, Saskia [2 ]
Schwind, Sebastian [2 ]
Metzeler, Klaus H. [2 ]
Herling, Marco [2 ]
Jentzsch, Madlen [2 ]
Franke, Georg-Nikolaus [2 ]
Sack, Ulrich [4 ]
Koehl, Ulrike [1 ,4 ]
Platzbecker, Uwe [2 ]
Reiche, Kristin [1 ,4 ,8 ]
Vucinic, Vladan [2 ]
Merz, Maximilian [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany
[2] Univ Hosp Leipzig, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[3] Univ Hosp Leipzig, Innovat Ctr Comp Assisted Surg, Leipzig, Germany
[4] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany
[5] Singleron Biotechnol, Cologne, Germany
[6] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[7] Univ Leipzig, Leipzig Med Biobank, Leipzig, Germany
[8] Ctr Scalable Data Analyt & Artificial Intelligence, Leipzig, Germany
关键词
THERAPY;
D O I
10.1038/s43018-024-00763-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma. Merz and colleagues perform single-cell multiomic analysis of mononuclear cells isolated from individuals receiving BCMA-directed CAR T cell therapy for myeloma and show that nonresponders are characterized by an immune-suppressive microenvironment.
引用
收藏
页码:1318 / 1333
页数:29
相关论文
共 50 条
  • [1] Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
    Yang, Xu
    Wang, Feiqing
    Yuan, Xiaoshuang
    Yang, Bo
    Chen, Juan
    Cheng, Jinyang
    Liu, Guangyang
    Tang, Dongxin
    Xu, Xiao
    Wang, Sanbin
    He, Zhixu
    Liu, Yang
    Li, Yanju
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Chimeric Antigen Receptor T Cells in Multiple Myeloma
    Shah, Parth
    Sperling, Adam S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1089 - 1105
  • [3] γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
    Pont, Margot J.
    Hill, Tyler
    Cole, Gabriel O.
    Abbott, Joe J.
    Kelliher, Jessica
    Salter, Alexander I.
    Hudecek, Michael
    Comstock, Melissa L.
    Rajan, Anusha
    Patel, Bharvin K. R.
    Voutsinas, Jenna M.
    Wu, Qian
    Liu, Lingfeng
    Cowan, Andrew J.
    Wood, Brent L.
    Green, Damian J.
    Riddell, Stanley R.
    BLOOD, 2019, 134 (19) : 1585 - 1597
  • [4] Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma
    Testa, Ugo
    Pelosi, Elvira
    Castelli, Germana
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [5] Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
    Hasanali, Zainul S.
    Razzo, Beatrice
    Susanibar-Adaniya, Sandra P.
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    Cohen, Adam D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 383 - 406
  • [6] B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis
    Gagelmann, Nico
    Ayuk, Francis
    Atanackovic, Djordje
    Kroeger, Nicolaus
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 318 - 327
  • [7] Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
    Shah, Urvi A.
    Smith, Eric L.
    CANCER JOURNAL, 2019, 25 (03) : 208 - 216
  • [8] Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma
    Hamadeh, Issam S.
    Friend, Reed
    Mailankody, Sham
    Atrash, Shebli
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
    Feng, Yaru
    Liu, Xiuying
    Li, Xiaorui
    Zhou, Yating
    Song, Zhiru
    Zhang, Jing
    Shi, Bingjie
    Wang, Jianxun
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [10] Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
    Kang, Liqing
    Zhang, Jian
    Li, Minghao
    Xu, Nan
    Qi, Wei
    Tan, Jingwen
    Lou, Xiaoyan
    Yu, Zhou
    Sun, Juanjuan
    Wang, Zhenkun
    Fu, Chengcheng
    Tang, Xiaowen
    Dai, Haiping
    Chen, Jia
    Wu, Depei
    Yu, Lei
    BIOMARKER RESEARCH, 2020, 8 (01)